FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2068449076> ?p ?o ?g. }

• W2068449076 endingPage "1814" @default.
• W2068449076 startingPage "1808" @default.
• W2068449076 abstract "This study of vosaroxin evaluated dose-limiting toxicity (DLT), maximum-tolerated dose (MTD), pharmacokinetics (PK), clinical activity and pharmacodynamics in relapsed/refractory leukemia. Dosing was weekly (days 1, 8 and 15) or twice weekly (days 1, 4, 8 and 11). Seventy-three treated patients had a median age of 65 years, 85% had acute myeloid leukemia and 78% had refractory disease. Weekly schedule: 42 patients received 18-90 mg/m(2); MTD was 72 mg/m(2). Twice-weekly schedule: 31 patients received 9-50 mg/m(2); MTD was 40 mg/m(2). DLT was stomatitis; primary non-hematologic toxicity was reversible gastrointestinal symptoms and febrile neutropenia. Thirty-day all-cause mortality was 11%. Five patients had complete or incomplete remissions; median duration was 3.1 months. A morphologic leukemia-free state (bone marrow blast reduction to <5%) occurred in 11 additional patients. Antileukemic activity was associated with total dose or weekly time above 1 μmol/l plasma vosaroxin concentration (P<0.05). Vosaroxin exposure was dose proportional over 9-90 mg/m(2). The average terminal half-life was ~25 h and clearance was non-renal. No induction or inhibition of vosaroxin metabolism was evident. Vosaroxin-induced DNA damage was detected as increased intracellular γH2AX. Vosaroxin had an acceptable safety profile, linear PK and encouraging clinical activity in relapsed/refractory leukemia." @default.
• W2068449076 created "2016-06-24" @default.
• W2068449076 creator A5000750846 @default.
• W2068449076 creator A5016061346 @default.
• W2068449076 creator A5020012790 @default.
• W2068449076 creator A5036251329 @default.
• W2068449076 creator A5040758762 @default.
• W2068449076 creator A5041443589 @default.
• W2068449076 creator A5050940843 @default.
• W2068449076 creator A5061285204 @default.
• W2068449076 creator A5065716888 @default.
• W2068449076 creator A5065872758 @default.
• W2068449076 creator A5083215091 @default.
• W2068449076 creator A5090435894 @default.
• W2068449076 date "2011-07-15" @default.
• W2068449076 modified "2023-10-16" @default.
• W2068449076 title "A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia" @default.
• W2068449076 cites W1492609361 @default.
• W2068449076 cites W1978547620 @default.
• W2068449076 cites W1985775217 @default.
• W2068449076 cites W1990431470 @default.
• W2068449076 cites W1990766453 @default.
• W2068449076 cites W1998973639 @default.
• W2068449076 cites W2002689332 @default.
• W2068449076 cites W2010655738 @default.
• W2068449076 cites W2035614371 @default.
• W2068449076 cites W2039795723 @default.
• W2068449076 cites W2044942890 @default.
• W2068449076 cites W2045045842 @default.
• W2068449076 cites W2053903261 @default.
• W2068449076 cites W2061414735 @default.
• W2068449076 cites W2068962067 @default.
• W2068449076 cites W2078936160 @default.
• W2068449076 cites W2104590411 @default.
• W2068449076 cites W2106688219 @default.
• W2068449076 cites W2117975005 @default.
• W2068449076 cites W2126922455 @default.
• W2068449076 cites W2143854006 @default.
• W2068449076 cites W2159507916 @default.
• W2068449076 cites W2764775166 @default.
• W2068449076 cites W4376595466 @default.
• W2068449076 doi "https://doi.org/10.1038/leu.2011.157" @default.
• W2068449076 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4576993" @default.
• W2068449076 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21760592" @default.
• W2068449076 hasPublicationYear "2011" @default.
• W2068449076 type Work @default.
• W2068449076 sameAs 2068449076 @default.
• W2068449076 citedByCount "40" @default.
• W2068449076 countsByYear W20684490762012 @default.
• W2068449076 countsByYear W20684490762013 @default.
• W2068449076 countsByYear W20684490762014 @default.
• W2068449076 countsByYear W20684490762015 @default.
• W2068449076 countsByYear W20684490762016 @default.
• W2068449076 countsByYear W20684490762017 @default.
• W2068449076 countsByYear W20684490762018 @default.
• W2068449076 countsByYear W20684490762019 @default.
• W2068449076 countsByYear W20684490762022 @default.
• W2068449076 crossrefType "journal-article" @default.
• W2068449076 hasAuthorship W2068449076A5000750846 @default.
• W2068449076 hasAuthorship W2068449076A5016061346 @default.
• W2068449076 hasAuthorship W2068449076A5020012790 @default.
• W2068449076 hasAuthorship W2068449076A5036251329 @default.
• W2068449076 hasAuthorship W2068449076A5040758762 @default.
• W2068449076 hasAuthorship W2068449076A5041443589 @default.
• W2068449076 hasAuthorship W2068449076A5050940843 @default.
• W2068449076 hasAuthorship W2068449076A5061285204 @default.
• W2068449076 hasAuthorship W2068449076A5065716888 @default.
• W2068449076 hasAuthorship W2068449076A5065872758 @default.
• W2068449076 hasAuthorship W2068449076A5083215091 @default.
• W2068449076 hasAuthorship W2068449076A5090435894 @default.
• W2068449076 hasBestOaLocation W20684490761 @default.
• W2068449076 hasConcept C111113717 @default.
• W2068449076 hasConcept C112705442 @default.
• W2068449076 hasConcept C121332964 @default.
• W2068449076 hasConcept C126322002 @default.
• W2068449076 hasConcept C141071460 @default.
• W2068449076 hasConcept C142424586 @default.
• W2068449076 hasConcept C2776863199 @default.
• W2068449076 hasConcept C2777063308 @default.
• W2068449076 hasConcept C2777288759 @default.
• W2068449076 hasConcept C2778461978 @default.
• W2068449076 hasConcept C2778496288 @default.
• W2068449076 hasConcept C2778729363 @default.
• W2068449076 hasConcept C2778850193 @default.
• W2068449076 hasConcept C29730261 @default.
• W2068449076 hasConcept C71924100 @default.
• W2068449076 hasConcept C87355193 @default.
• W2068449076 hasConcept C90924648 @default.
• W2068449076 hasConcept C98274493 @default.
• W2068449076 hasConceptScore W2068449076C111113717 @default.
• W2068449076 hasConceptScore W2068449076C112705442 @default.
• W2068449076 hasConceptScore W2068449076C121332964 @default.
• W2068449076 hasConceptScore W2068449076C126322002 @default.
• W2068449076 hasConceptScore W2068449076C141071460 @default.
• W2068449076 hasConceptScore W2068449076C142424586 @default.
• W2068449076 hasConceptScore W2068449076C2776863199 @default.
• W2068449076 hasConceptScore W2068449076C2777063308 @default.
• W2068449076 hasConceptScore W2068449076C2777288759 @default.

• next